{"title":"A Single Nucleotide Polymorphism in the MMP9 Promoter Affects Lung Cancer and Clinicopathological Properties in Iranian Population","authors":"Somayeh Taghvaei, L. Saremi, M. Motovali-bashi","doi":"10.37871/jbres1382","DOIUrl":null,"url":null,"abstract":"Background: Lung cancer is the most common cancer with 2,206,771 new cases in 2020 in worldwide. MMP9 is a member of matrix metalloproteinase family that is also known as gelatinase B or IV type collagenase (92KD). MMP9 through degrading of Extracellular Matrix (ECM) and releasing of growth factors has fundamental role in the tumorigenesis process. The C -1562 T SNP in the MMP9 promoter increases MMP9 expression and susceptibility to lung cancer. Then, the aim of this present case-control study was to investigate whether genetic variations of the MMP9 gene may constitute markers for lung cancer risk in males and in positive family history people in Iran. Methods: This is a case-control study including 120 lung cancer patients and 100 healthy controls. Polymorphism in the C -1562 T region was genotyped by PCR-RFLP assay. Odds Ratio (ORs) and 95% Confidence Intervals (CIs) were estimated by chi-square test from comparison of genotypes between lung cancer patients and healthy controls, using SPSS version 26.0. T-test and Image J software was also used. Results: The distribution of C-1562T genotype was significantly associated with the risk of lung cancer (Odds Ratio [OR] = 2.56, 95% Confidence Interval [CI] = 0.06-23.82). The further stratification analyses shown that males and patients with positive family history may increase risk of lung cancer. Conclusion: Our results indicated that the MMP9 C -1562 T polymorphism affects risk of lung cancer. In addition, men with T allele (OR = 3.94, CI = 1.47-10`.55) and patients with TT genotype and family history (OR = 2.18, CI = 1.03-4.59) exposure to higher risk of lung cancer.","PeriodicalId":94067,"journal":{"name":"Journal of biomedical research & environmental sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical research & environmental sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37871/jbres1382","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Lung cancer is the most common cancer with 2,206,771 new cases in 2020 in worldwide. MMP9 is a member of matrix metalloproteinase family that is also known as gelatinase B or IV type collagenase (92KD). MMP9 through degrading of Extracellular Matrix (ECM) and releasing of growth factors has fundamental role in the tumorigenesis process. The C -1562 T SNP in the MMP9 promoter increases MMP9 expression and susceptibility to lung cancer. Then, the aim of this present case-control study was to investigate whether genetic variations of the MMP9 gene may constitute markers for lung cancer risk in males and in positive family history people in Iran. Methods: This is a case-control study including 120 lung cancer patients and 100 healthy controls. Polymorphism in the C -1562 T region was genotyped by PCR-RFLP assay. Odds Ratio (ORs) and 95% Confidence Intervals (CIs) were estimated by chi-square test from comparison of genotypes between lung cancer patients and healthy controls, using SPSS version 26.0. T-test and Image J software was also used. Results: The distribution of C-1562T genotype was significantly associated with the risk of lung cancer (Odds Ratio [OR] = 2.56, 95% Confidence Interval [CI] = 0.06-23.82). The further stratification analyses shown that males and patients with positive family history may increase risk of lung cancer. Conclusion: Our results indicated that the MMP9 C -1562 T polymorphism affects risk of lung cancer. In addition, men with T allele (OR = 3.94, CI = 1.47-10`.55) and patients with TT genotype and family history (OR = 2.18, CI = 1.03-4.59) exposure to higher risk of lung cancer.